Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

669 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study.
Schäkel K, Reich K, Asadullah K, Pinter A, Jullien D, Weisenseel P, Paul C, Gomez M, Wegner S, Personke Y, Kreimendahl F, Chen Y, Angsana J, Leung MWL, Eyerich K. Schäkel K, et al. Among authors: pinter a. J Eur Acad Dermatol Venereol. 2023 Oct;37(10):2016-2027. doi: 10.1111/jdv.19236. Epub 2023 Jul 18. J Eur Acad Dermatol Venereol. 2023. PMID: 37262309 Clinical Trial.
Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study.
Thaçi D, Puig L, Reich K, Tsai TF, Tyring S, Kingo K, Ziv M, Pinter A, Vender R, Lacombe A, Xia S, Bhosekar V, Gilloteau I, Guana A, Blauvelt A. Thaçi D, et al. Among authors: pinter a. J Am Acad Dermatol. 2019 Dec;81(6):1405-1409. doi: 10.1016/j.jaad.2019.04.045. Epub 2019 Aug 6. J Am Acad Dermatol. 2019. PMID: 31399223 Free article. Clinical Trial. No abstract available.
A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE).
Pinter A, Hoffmann M, Reich K, Augustin M, Kaplan K, Gudjónsdóttir SD, Delvin T, Mrowietz U; CHANGE investigator group. Pinter A, et al. J Eur Acad Dermatol Venereol. 2021 Mar;35(3):701-711. doi: 10.1111/jdv.16932. Epub 2020 Dec 23. J Eur Acad Dermatol Venereol. 2021. PMID: 32939860 Clinical Trial.
Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment.
Leutz A, Pinter A, Thaçi D, Augustin M, Schuster C, Fotiou K, Hundemer HP, Saure D, Mrowietz U, Reich K. Leutz A, et al. Among authors: pinter a. Br J Dermatol. 2021 Mar;184(3):548-550. doi: 10.1111/bjd.19558. Epub 2020 Nov 10. Br J Dermatol. 2021. PMID: 32940343 No abstract available.
Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial.
Thaçi D, Soliman AM, Eyerich K, Pinter A, Sebastian M, Unnebrink K, Rubant S, Williams DA, Weisenseel P. Thaçi D, et al. Among authors: pinter a. J Eur Acad Dermatol Venereol. 2021 Aug;35(8):1686-1691. doi: 10.1111/jdv.17109. Epub 2021 Jul 12. J Eur Acad Dermatol Venereol. 2021. PMID: 33428281 Clinical Trial.
Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study.
Mrowietz U, Burden AD, Pinter A, Reich K, Schäkel K, Baum P, Datsenko Y, Deng H, Padula SJ, Thoma C, Bissonnette R. Mrowietz U, et al. Among authors: pinter a. Dermatol Ther (Heidelb). 2021 Apr;11(2):571-585. doi: 10.1007/s13555-021-00504-0. Epub 2021 Mar 4. Dermatol Ther (Heidelb). 2021. PMID: 33661508 Free PMC article.
Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study.
Silverberg JI, Pinter A, Alavi A, Lynde C, Bouaziz JD, Wollenberg A, Murrell DF, Alpizar S, Laquer V, Chaouche K, Ahmad F, Armstrong JM, Piketty C. Silverberg JI, et al. Among authors: pinter a. J Eur Acad Dermatol Venereol. 2021 Jul;35(7):1562-1568. doi: 10.1111/jdv.17218. Epub 2021 Apr 1. J Eur Acad Dermatol Venereol. 2021. PMID: 33711179 Clinical Trial.
IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE).
Eyerich K, Weisenseel P, Pinter A, Schäkel K, Asadullah K, Wegner S, Muñoz-Elias EJ, Bartz H, Taut FJH, Reich K. Eyerich K, et al. Among authors: pinter a. BMJ Open. 2021 Sep 13;11(9):e049822. doi: 10.1136/bmjopen-2021-049822. BMJ Open. 2021. PMID: 34518264 Free PMC article.
669 results